Summit Therapeutics Inc. (SMMT)
$
15.72
+0.12 (0.76%)
Key metrics
Financial statements
Free cash flow per share
-0.4328
Market cap
11.7 Billion
Price to sales ratio
0
Debt to equity
0.0235
Current ratio
9.8688
Income quality
0.2991
Average inventory
0
ROE
-2.9682
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Summit Therapeutics Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines aimed at treating infectious diseases in the United States and Latin America. The firm has a clinical program primarily dedicated to combating Clostridioides difficile infection (CDI), with ridinilazole as its lead product candidate. This orally administered small molecule antibiotic is currently in Phase III clinical trials for CDI treatment. In addition to ridinilazole, Summit Therapeutics offers SMT-738, targeting multidrug-resistant infections, particularly those caused by carbapenem-resistant Enterobacteriaceae, as well as the DDS-04 series designed for the potential treatment of Enterobacteriaceae-related infections. Despite its innovative advancements, the company reported a net loss of -$1,079,586,000.00 indicating challenges in its operations. The gross profit ratio stands at 0.00 showcasing the efficiency of its production and sales processes. Moreover, the EBITDA ratio of 0.00 highlights operational efficiency, even as the company faces selling, general, and administrative expenses of $556,750,000.00 reflecting its operational overhead costs. The company’s stock is traded under the symbol 'SMMT' in the market, providing investors with insight into its financial performance. The stock is affordable at $18.89 catering to budget-conscious investors who are looking for opportunities in the biopharmaceutical space. Additionally, the stock enjoys a high average trading volume of 2,536,366.00 which indicates strong liquidity and investor interest. With a mid-range market capitalization of $11,702,643,960.00 the company is regarded as a steady performer within its sector. As a key player in the Biotechnology industry, Summit Therapeutics contributes significantly to the overall market landscape, driving innovation and growth. Belonging to the Healthcare sector, it plays a crucial role in advancing solutions to pressing health challenges, continuing to pave the way for new treatments amid its ongoing clinical trials and research initiatives.
Is Summit Therapeutics Inc. (SMMT) a good investment?
Investing in Summit Therapeutics Inc. (SMMT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Summit Therapeutics Inc. (SMMT)'s stock forecast?
Analysts predict Summit Therapeutics Inc. stock to fluctuate between $13.83 (low) and $36.91 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Summit Therapeutics Inc.'s market capitalization?
As of 2026-03-19, Summit Therapeutics Inc.'s market cap is $11,702,643,960, based on 744,443,000 outstanding shares.
How does Summit Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Summit Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Summit Therapeutics Inc. (SMMT) stock?
To buy Summit Therapeutics Inc. (SMMT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SMMT. Place an order (Market, Limit, etc.).
What is the best time to invest in Summit Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Summit Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.44 | Growth: 364.52%.
Where can I find Summit Therapeutics Inc.'s investor relations reports?
Visit https://www.summittxinc.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Summit Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Summit Therapeutics Inc. stock?
All-time high: $36.91 (2025-04-24) | All-time low: $0.66 (2022-12-02).
What are the key trends affecting Summit Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
seekingalpha.com
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
businesswire.com
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday.
zacks.com
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
seekingalpha.com
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
businesswire.com
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our.
zacks.com
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
businesswire.com
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy. The FDA.
businesswire.com
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for ivonescimab, the novel, first-in-class investigational bispecific antibody, in combination with chemotherapy in second-line or later treatment of patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-.
fool.com
In a previous clinical trial, Summit's cancer drug ivonescimab showed it was more effective than Keytruda. The excitement propelled Summit's stock to a valuation that at one point reached $27 billion.
See all news
